CGTLive®’s Weekly Rewind – May 31, 2024

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR T Therapy Shows Some Significant Responses in High Grade Glioma

Fifty percent of patients had stable disease or better, with 2 complete responses and 2 partial responses.

2. Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain

The head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed research from the center presented at ASGCT 2024.

3. CAR TEAM Cells Show Dramatic, Short-Lived Responses in Glioblastoma

Transient responses in 2 of 3 participants may be due to limited persistence of CARv3-TEAM-E T-cells in the weeks after infusion.

4. Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials

The associate professor of otolaryngology from Harvard Medical School also shared his excitement for the positive data on AAV1-hOTOF.

5. Aurion Biotech Evaluating Combination Cell Therapy Product AURN001 as Alternative to Corneal Transplant in Phase 1/2 ABA-1, CLARA Clinical Trial

In honor of Healthy Vision Month, CGTLive® took a closer look at the clinical trial design for this novel treatment.